All news

Wells Fargo starts Design Therapeutics at Overweight

Alpha Vantage · marketscreener.com · · AI-summarised by FinFlash

Wells Fargo initiated coverage on Design Therapeutics (NasdaqGS:DSGN) with an Overweight rating and a $26 price target. The call follows the biotechnology company's recent addition to the S&P Biotechnology Select Industry Index and its second-quarter earnings report. Design Therapeutics develops GeneTACT molecules targeting diseases caused by inherited nucleotide repeat expansion mutations, with programs focused on Friedreich ataxia and Fuchs endothelial corneal dystrophy.

Read original source

DSGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.